| 1.15 0.03 (2.68%) | 11-10 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.89 | 1-year : | 2.3 |
| Resists | First : | 1.61 | Second : | 1.97 |
| Pivot price | 1.27  |
|||
| Supports | First : | 1.04 | Second : | 0.87 |
| MAs | MA(5) : | 1.12 |
MA(20) : | 1.29 |
| MA(100) : | 1.58 |
MA(250) : | 1.76 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 14 |
D(3) : | 11.9 |
| RSI | RSI(14): 36.3 |
|||
| 52-week | High : | 2.74 | Low : | 1.04 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ MAIA ] has closed above bottom band by 27.1%. Bollinger Bands are 65.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.15 - 1.16 | 1.16 - 1.16 |
| Low: | 1.11 - 1.11 | 1.11 - 1.12 |
| Close: | 1.14 - 1.15 | 1.15 - 1.16 |
MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer, primarily non-small cell lung cancer. Its lead asset, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded in 2018 and is headquartered in Chicago, Illinois.
Tue, 11 Nov 2025
Will MAIA Biotechnology Inc. stock recover after recent drop - July 2025 Trends & Free Weekly Chart Analysis and Trade Guides - newser.com
Tue, 11 Nov 2025
What MACD and RSI say about MAIA Biotechnology Inc. - 2025 Major Catalysts & High Conviction Trade Alerts - newser.com
Tue, 11 Nov 2025
Will MAIA Biotechnology Inc. stock rise with strong economy - Weekly Risk Summary & Reliable Volume Spike Trade Alerts - newser.com
Mon, 10 Nov 2025
Will MAIA Biotechnology Inc. stock return to pre crash levels - Portfolio Risk Report & Weekly Chart Analysis and Trade Guides - newser.com
Mon, 10 Nov 2025
Will MAIA Biotechnology Inc. stock see PE expansion - 2025 Year in Review & Daily Stock Trend Reports - newser.com
Mon, 10 Nov 2025
How to use a screener to detect MAIA Biotechnology Inc. breakouts - July 2025 Highlights & Technical Entry and Exit Alerts - newser.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
AMEX
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 24 (M) |
| Shares Float | 19 (M) |
| Held by Insiders | 16.3 (%) |
| Held by Institutions | 7.4 (%) |
| Shares Short | 633 (K) |
| Shares Short P.Month | 777 (K) |
| EPS | -1.63 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.12 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -107.2 % |
| Return on Equity (ttm) | -559.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -15 (M) |
| Levered Free Cash Flow | -9 (M) |
| PE Ratio | -0.71 |
| PEG Ratio | 0 |
| Price to Book value | 8.84 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.79 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|